Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 205972
Company: AUROBINDO PHARMA

Products on ANDA 205972

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 2.5MG BASE	TABLET;ORAL	Prescription	AB	No	No
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 5MG BASE	TABLET;ORAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 205972

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
07/31/2023	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/205972Orig1s000TAltr.pdf

Therapeutic Equivalents for ANDA 205972

SAXAGLIPTIN

TABLET;ORAL; EQ 2.5MG BASE
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 2.5MG BASE	TABLET;ORAL	Prescription	No	AB	205972	AUROBINDO PHARMA
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 2.5MG BASE	TABLET;ORAL	Prescription	No	AB	205994	GLENMARK PHARMS LTD
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 2.5MG BASE	TABLET;ORAL	Prescription	No	AB	205980	MYLAN
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 2.5MG BASE	TABLET;ORAL	Prescription	No	AB	206078	SUN PHARM

TABLET;ORAL; EQ 5MG BASE
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 5MG BASE	TABLET;ORAL	Prescription	No	AB	205972	AUROBINDO PHARMA
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 5MG BASE	TABLET;ORAL	Prescription	No	AB	205994	GLENMARK PHARMS LTD
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 5MG BASE	TABLET;ORAL	Prescription	No	AB	205980	MYLAN
SAXAGLIPTIN	SAXAGLIPTIN HYDROCHLORIDE	EQ 5MG BASE	TABLET;ORAL	Prescription	No	AB	206078	SUN PHARM